1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
United Orthopedic Corporation

United Orthopedic Corporation

TTPEX:4129
77.00
TWD
+0.90
(+1.18%)
5.51EPS
16.04P/E
8.84BMarket Cap
Nov 11Next Earn
United Orthopedic Corporation
TPEX:4129
(Taipei Exchange)

Recent

price

77.00

P/E

ratio

16.04

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
14.4
15.03
17.42
17.4
20.01
23.37
19.45
26.99
29.37
30.57
29.9
33.02
40.57
46.61
48.42
58.64
62.89
Revenue per Share
0.69
1.15
0.77
0.39
1.49
2.25
2.06
1.78
1.61
1.11
1.3
0.67
2.84
4.56
4.75
5.83
5.72
Basic EPS, GAAP
-0.23
-1.12
-2.56
-3.76
-1.62
0.74
-2.98
-7.7
-4.52
2.82
3.43
1.48
-0.38
-1.47
1.33
2.74
-0.91
Free Cash Flow per Basic Share
0.84
0.62
0.94
0.39
0.45
1.14
1.61
1.36
1.26
2.02
0.88
1.14
- -
2.38
4.02
4
- -
Dividend per Share
12.31
12.49
12.21
14.98
16.96
24.33
24.15
27.66
28
33.91
33.81
33.57
36.93
39.82
39.95
42.51
40.47
Book Value per Share
12.2
12.13
11.78
14.51
16.61
24.12
23.63
22.2
22.08
27.69
27.26
26.93
29.62
33.31
33.96
36.3
34.33
Tangible Book Value per Share
51
51
49
55
55
60
71
73
79
80
78
78
78
84
96
96
96
Basic Weighted Avg Shares
728
760
860
956
1,101
1,393
1,383
1,973
2,332
2,437
2,342
2,571
3,169
3,930
4,653
5,655
6,067
Sales/Revenue/Turnover
8.29
6.66
5.93
2.18
9.22
12.87
11.54
8.21
3.5
3.38
3.84
6.22
11.01
13.66
13.41
13.03
11.31
Operating Margin (%)
48
57
72
86
107
124
104
150
215
270
287
310
335
396
460
539
597
Depreciation Expense
35
58
38
21
82
134
147
130
128
89
102
52
222
384
456
562
552
Net Income, GAAP
27.57
21.32
19.37
42.11
24.91
19.28
11.25
33.03
4.61
20.89
7.19
29.11
26.22
23.75
19.95
24.45
24.17
Effective Tax Rate (%)
4.81
7.62
4.4
2.23
7.42
9.61
10.6
6.6
5.47
3.64
4.35
2.03
6.99
9.78
9.81
9.95
9.09
Profit Margin (%)
377
349
170
528
401
1,225
661
671
781
1,051
940
490
905
1,493
1,352
1,790
1,416
Working Capital
113
144
130
397
192
148
156
614
885
945
882
405
711
856
515
1,002
1,100
LT Debt
623
631
618
851
1,011
1,773
1,802
2,218
2,250
2,934
2,925
2,821
3,090
3,594
3,950
4,204
4,005
Total Equity
5.68
4.79
4.26
0.96
4.92
7.8
6.22
3.54
2.06
1.46
1.76
2.42
5.52
8.24
8.7
9.08
8.87
Return on Invested Capital (%)
4.69
7.37
4.45
2.15
5.9
7.82
7.03
5.24
4.56
3.01
2.8
1.37
5.15
8.37
8.82
9.74
9.98
Return on Capital (%)
5.55
9.24
6.05
2.91
8.78
9.61
8.27
6.55
5.75
3.57
3.74
1.96
8.03
12.03
12.43
14.15
14.54
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,058
1,158
1,261
LT Borrowings
813
792
772
LT Finance Leases
189
323
328
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
10,801
9,432
8,843

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,290
4,508
4,711
Cash, Cash Equivalents & STI
663
643
580
Accounts Receivable, Net
1,302
1,398
1,438
Inventories
2,074
2,226
2,410
Total Current Liabilities
2,500
2,723
3,295
Payables & Accruals
- -
- -
- -
ST Debt
1,058
1,158
1,261
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.49%
7.73%
6.44%
Free Cash Flow
-55.41%
8.43%
106.79%
Net Income, GAAP
37.14%
78.12%
23.24%
Sales/Revenue/Turnover
15.77%
19.39%
21.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,066
1,141
1,131
1,316
4,653
2025
1,297
1,351
1,492
1,516
5,655
2026
1,494
1,565
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.98
1.06
1.44
1.27
4.75
2025
1.98
0.48
2.01
1.36
5.83
2026
0.91
1.44
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.02
2025
- -
- -
- -
- -
4
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
United Orthopedic Corporation engages in the design, development, production, and global distribution of advanced orthopedic implant solutions and their corresponding surgical instrumentation. The enterprise provides an extensive selection of hip replacement systems, including options for primary procedures, complex revisions, limb salvage, and custom implants for oncology patients. Its offerings extend to a broad range of knee systems, featuring both primary and revision knee replacement devices tailored to diverse surgical requirements. Additionally, the company supplies trauma and internal fixation products such as bone plates, nails, pins, and screws. It supports healthcare providers with vital clinical education and dedicated customer service. Operating with a vertically integrated manufacturing process, United Orthopedic ensures stringent quality control and efficient responsiveness in bringing its innovative products to market. Founded in 1993 and based in New Taipei City, Taiwan, the company maintains a significant international footprint, serving over 52 countries across Asia, the Americas, Europe, Africa, and Australia through its network of nine global branch offices. Demonstrating sustained expansion, the firm recently achieved record-high revenues in the first quarter of 2025. Its clinically proven products have facilitated over 770,000 surgeries, underscoring its commitment to enhancing patient outcomes worldwide.